Skip to main content
. 2016 Jan 4;35(32):4225–4234. doi: 10.1038/onc.2015.487

Table 1. The breast and lung cancer cell lines we examined are ranked by relative MUCL1 mRNA expression as determined in NextBio.com.

Cell line Cancer type Fold expression change ER/PR/HER2 status Molecular subtype
KPL-4 Breast 269 −/−/++ HER2
JIMT-1 Breast 204.1 −/−/++ HER2
MDA-MB-361 Breast 174.3 +/+/++ LUM B
ZR-75-1 Breast 116.6 +/+/+ LUM B
MDA-MB-175-VII Breast 58.6 +/−/− LUM A
HCC1419 Breast 46.4 −/−/++ HER2
HCC202 Breast 31.7 −/−/++ HER2
BT-474 Breast 30.7 −/+/++ LUM B
MDA-MB-415 Breast 29.6 +/−/− LUM A
MDA-MB-134-VI Breast 14.2 +/−/− LUM A
HCC1428 Breast 14.1 +/+/− LUM A
HCC1954 Breast 12.6 −/−/+ HER2
DU4475 Breast 11.3 −/−/− Basal
SK-BR-3 Breast 9.4 −/−/++ HER2
ZR-75-30 Breast 9.3 +/−/++ LUM B
HCC70 Breast 6.4 +/−/− LUM A
MCF7 Breast 5.4 +/+/− LUM A
MDA-MB-468 Breast 4.0 −/−/− Basal
HCC38 Breast 3.7 −/−/− Basal
HCC1937 Breast 0.9 −/−/− Basal
NCI-H460 Lung 213.5 HER2 + Large cell
NCI-H520 Lung 150.2 HER2 − Squamous cell

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MUCL1, Mucin-like 1; PR, progesterone receptor.

Fold expression change represents the level of MUCL1 in each cell line divided by the median of the gene across all normal cell lines. The ER, PR and HER2 status as well as the molecular subtype of each cancer cell line are reported.